Rapid Rx Quiz: Diabetes Drugs

Mary L. Windle, PharmD

Disclosures

May 13, 2022

Patients taking semaglutide at 0.5 mg/wk subcutaneously (SC) should transition to 7 mg or 14 mg orally starting up to 7 days after their last injection. The initial dose of oral semaglutide is 3 mg/d for 30 days. The 3-mg dose is intended for treatment initiation and is not effective for glycemic control. After 30 days on 7 mg/d, patients may increase dose to 14 mg/d if additional glycemic control is needed; however, taking two 7-mg tablets to achieve 14 mg dose is not recommended. Oral semaglutide is not recommended as a first-line therapy for patients who have inadequate glycemic control on diet and exercise.

Learn more about semaglutide.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....